በካሊፎርኒያ ለደርማቲቲስ የሚደረጉ ክሊኒካዊ ጥናቶች
ለደርማቲቲስ የሚደረጉ 6 ጥናቶች በካሊፎርኒያ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በካሊፎርኒያ ውስጥ ያሉ ከተሞች
Official study text (English)
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Fountain Valley
- Novartis Investigative Site, Los Angeles
- Novartis Investigative Site, Sacramento
- እና 2 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 100 · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT06947993First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
- Alliance Clinical West Hills (Focus Clinical Research), West Hills
ተሳታዮችን በመፈለግ ላይደረጃ 1ጤናማ ተሳታዮች ይቀበላሉ
እድሜ ከ18 እስከ 65 · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT07527923A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
- Investigational Drug Service - Rady Childrens Hospital-San Diego, San Diego
- University of California, San Diego/Rady Children's Hospital-San Diego; Pediatric & Adolescent Derm, San Diego
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ ከ6 እስከ 11 · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06807268A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
- Northridge Clinical Trials, Northridge
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ሴፕቴ 2026 · NCT07765888A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Marvel Research, LLC, Huntington Beach
- Metropolis Dermatology, Los Angeles
- Dermatology Research Associates, Los Angeles
- እና 4 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 65 · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦገስ 2026 · NCT07599813A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 1, Lancaster
- Inmagene Site 23, Los Angeles
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 74 · ሁሉም ጾታዎች · የተሻሻለው በ12 ኦገስ 2026 · NCT07037901ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።